Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States

BACKGROUND: Axicabtagene ciloleucel (Axi-cel) is the first Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) product approved in China for treating adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or above systemic therapy. However, it cannot be widel...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Lei, Jianying, Zhang, Jiahao, Cai, Hongfu, Zheng, Bin, Yang, Ting, Liu, Maobai, Hu, Jianda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214081/
https://www.ncbi.nlm.nih.gov/pubmed/37250912
http://dx.doi.org/10.1177/20406207231168215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214081/
https://www.ncbi.nlm.nih.gov/pubmed/37250912
http://dx.doi.org/10.1177/20406207231168215

Ejemplares similares